MINDRAY is launching its new A8 and A9 anaesthesia machines in the UK market, which feature integrated high flow nasal cannula (HFNC) technology.
This technology helps to extend the window of therapeutic action for anaesthetists by prolonging safe apnoeic oxygenation levels, allowing up to 30 minutes of safe oxygenated apnoea time. Studies have found that HFNC can more than double the average duration of apnoea before desaturation.
Data from a wide range of external monitoring modules – such as bispectral index, neuromuscular transmission and intravenous imaging – can be seamlessly integrated and displayed by the new devices without any extra monitoring screens. Enabling anaesthetists to collect more data at a glance, the modular design also fulfils the need for fewer devices in theatre, allowing anaesthetists to utilise a larger workspace and spend more time closely observing their patients.
In order to optimise gas usage and quickly provide a balanced response to changes in patient status without user intervention, the A9 uses Automatic Controlled Anaesthesia (ACA). Through its precision electronic vaporiser and ACA platform, the A9 adjusts fresh gas and vaporiser output to hit patient targets using both end-tidal and inspiratory oxygen measurements.
The new systems also utilise a suite of gas reduction tools to minimise the environmental and economic impact of surgery by preventing leakage and managing usage, improving patient safety in the process. Both the A8 and A9 can offer suggestions on optimal fresh gas flow, provide real-time usage metrics, pause to prevent leakage, and indicate flow rate abnormalities.
